BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9927049)

  • 1. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription.
    Nawaz Z; Stancel GM; Hyder SM
    Cancer Res; 1999 Jan; 59(2):372-6. PubMed ID: 9927049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
    Rosenberg Zand RS; Grass L; Magklara A; Jenkins DJ; Diamandis EP
    Breast Cancer Res Treat; 2000 Mar; 60(1):1-8. PubMed ID: 10845803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent specific pure antiestrogen with clinical potential.
    Wakeling AE; Dukes M; Bowler J
    Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M
    Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.
    Bardon S; Vignon F; Montcourrier P; Rochefort H
    Cancer Res; 1987 Mar; 47(5):1441-8. PubMed ID: 3815345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
    DeFriend DJ; Howell A; Nicholson RI; Anderson E; Dowsett M; Mansel RE; Blamey RW; Bundred NJ; Robertson JF; Saunders C
    Cancer Res; 1994 Jan; 54(2):408-14. PubMed ID: 8275477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
    Jeng MH; Parker CJ; Jordan VC
    Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.
    García-López P; Rodríguez-Dorantes M; Pérez-Cárdenas E; Cerbón M; Mohar-Betancourt A
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):533-40. PubMed ID: 15138713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
    Nishino Y; Schneider MR; Michna H
    J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists.
    Wilson VS; Bobseine K; Gray LE
    Toxicol Sci; 2004 Sep; 81(1):69-77. PubMed ID: 15166400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.
    Hyder SM; Stancel GM
    Cancer Lett; 2002 Jul; 181(1):47-53. PubMed ID: 12430178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).
    Gu Z; Lee RY; Skaar TC; Bouker KB; Welch JN; Lu J; Liu A; Zhu Y; Davis N; Leonessa F; Brünner N; Wang Y; Clarke R
    Cancer Res; 2002 Jun; 62(12):3428-37. PubMed ID: 12067985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780.
    Huynh H; Nickerson T; Pollak M; Yang X
    Clin Cancer Res; 1996 Dec; 2(12):2037-42. PubMed ID: 9816164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.
    Kumar NS; Richer J; Owen G; Litman E; Horwitz KB; Leslie KK
    Cancer Res; 1998 May; 58(9):1860-5. PubMed ID: 9581825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474.
    Luo LY; Grass L; Diamandis EP
    Anticancer Res; 2000; 20(2A):981-6. PubMed ID: 10810385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.